AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference

   AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare
                                  Conference

PR Newswire

REDWOOD CITY, Calif., April 4, 2014

REDWOOD CITY, Calif., April 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that Richard King, President and
CEO, and Timothy E. Morris, CFO, will present a Company update on April 9^th.
Presentation details are as follows:

13^th Annual Needham Healthcare Conference
Date: Wednesday, April 9, 2014
Location: The Westin NY Grand Central Hotel, NY
Presentation Time: 10:40 am ET, 7:40 am PT

This presentation will be webcast live and can be accessed through the
Investors page at www.acelrx.com. For those not available to listen to the
live broadcast, a replay of this presentation will be archived for 90 days and
available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. AcelRx's lead product candidate,
Zalviso™, is designed to improve the management of moderate-to-severe acute
pain in patients in the hospital setting by utilizing a high therapeutic index
opioid, through a non-invasive delivery route via a pre-programmed
patient-controlled analgesia device.AcelRx has announced positive results
from each of the three completed Phase 3 clinical trials for Zalviso, and has
submitted an NDA to the FDA seeking approval for Zalviso in the treatment of
moderate-to-severe acute pain in adult patients in the hospital setting.
AcelRx plans to initiate a Phase 3 clinical trial for ARX-04, a product
candidate for the treatment of moderate-to-severe acute pain in a medically
supervised setting, during the second half of 2014.The company has two
additional pain treatment product candidates, ARX-02 and ARX-03, which have
completed Phase 2 clinical development.For additional information about
AcelRx's clinical programs, please visit www.acelrx.com

Forward-Looking Statements

This press release contains forward-looking statements, including, but not
limited to, statements related to submission of the NDA for Zalviso, planned
or anticipated future clinical development of AcelRx Pharmaceuticals' product
candidates, including planned Phase 3 clinical trial for ARX-04, and the
therapeutic potential of Zalviso and other AcelRx Pharmaceuticals' product
candidates. These forward-looking statements are based on AcelRx
Pharmaceuticals' current expectations and inherently involve significant risks
and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of
events could differ materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which include,
without limitation, risks related to: AcelRx's ability to receive regulatory
approval for Zalviso; any delays or inability to obtain and maintain
regulatory approval of its product candidates, including Zalviso, inthe
United StatesandEurope; the success, cost and timing of AcelRx
Pharmaceuticals' product development activities and clinical trials, including
planned Phase 3 clinical trial for ARX-04; the market potential for its
product candidates; and other risks detailed in the "Risk Factors" and
elsewhere in AcelRx's U.S. Securities and Exchange Commission filings and
reports, including its Annual Report on Form 10-K filed with the SEC on March
17, 2014. AcelRx undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of new
information, future events or changes in its expectations.

AcelRx logo.

Logo - http://photos.prnewswire.com/prnh/20130226/MM67303LOGO

SOURCE AcelRx Pharmaceuticals, Inc.

Website: http://www.acelrx.com
Contact: Tim Morris, Chief Financial Officer, 650.216.3511,
tmorris@acelrx.com; or Brian Korb, The Trout Group LLC, 646.378.2923,
bkorb@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.